Moderna, Inc.

MRNA

US60770K1079

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 20:00:00 13/03/2026 GMT			5-day change	1st Jan Change
52.56 ^USD	-1.55%		+0.08%	+78.23%

03-13	GSK gets US FDA approval for expanded use of RSV vaccine	RE
03-10	Moderna, Inc. Presents at Barclays 28th Annual Global Healthcare Conference, Mar-10-2026 09:30 AM

Health Care Up as FDA Fears Subside - Health Care Roundup

Published on 02/18/2026 at 10:49 pm GMT

Dow Jones

MODERNA, INC.

-1.55%

JOHNSON & JOHNSON

-0.21%

Health-care companies ticked up as fears about a new U.S. approach to drug regulation subsided.

The Food and Drug Administration reversed course and agreed to begin a review of Moderna's application to sell a new seasonal flu shot after the vaccine maker agreed to conduct additional testing in the elderly. Shares of Moderna rallied.

Johnson & Johnson will invest more than $1 billion in a next generation cell therapy manufacturing facility in Montgomery County, Pa.

Write to Rob Curran at rob.curran@dowjones.com

(END) Dow Jones Newswires

02-18-26 1748ET

Stocks mentioned in the article

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Price	Change	5d. change	Capi.
	MODERNA, INC.	52.56USD	-1.55%	+0.08%	20.76B
	JOHNSON & JOHNSON	241.52USD	-0.21%	+0.47%	582B

Latest news about Moderna, Inc.

03-13	GSK gets US FDA approval for expanded use of RSV vaccine	RE
03-10	Moderna, Inc. Presents at Barclays 28th Annual Global Healthcare Conference, Mar-10-2026 09:30 AM
03-05	Berenberg Raises Price Target on Moderna to $45 From $32, Keeps Hold Rating	MT
03-05	US stocks close up on Iran diplomacy hopes; tech leads rebound	RE
03-04	Health Care Up, But not by Much, on Cyclical Bias - Health Care Roundup	DJ
03-04	Equities Rise on Upbeat Data as Markets Look Past Middle East Conflict	MT
03-04	US Equity Markets End Higher After Strong Services, Jobs Data	MT
03-04	Moderna Shares Rise After Company Enters Settlement Agreement with Arbutus Biopharma, Genevant Sciences	MT
03-04	Equities Rise Intraday as Markets Parse Macro Data Amid Middle East Conflict	MT
03-04	US stocks close up on Iran diplomacy hopes; tech leads rebound	RE
03-04	Wall Street mixed as oil retreat eases inflation fears
03-04	Top Midday Stories: Bessent Says US to Fortify Gulf Oil Trade, 15% Tariff Rolling Out This Week; CrowdStrike Fiscal Q4 Adjusted Earnings, Revenue Increase	MT
03-04	Moderna rises on $2.25 billion settlement, clearing COVID vaccine patent dispute overhang	RE
03-04	Global markets live: Goldman Sachs, Meta, Intel, Moderna, Adidas…
03-04	Moderna to pay $950m to end litigation

Chart Moderna, Inc.

Duration

Period

MRNA: Dynamic Chart

Company Profile

Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows: - revenue from product sales (96.1%); - revenue from collaboration agreements (1.5%); - revenue from royalties and licensing (1.3%); - revenue from grants (1.1%). At the end of 2024, the group's portfolio comprises 37 products in clinical development, of which 10 in phase I, 18 in phase II and 9 in phase III, 3 products in preclinical development, and 4 products in commercial phase. Net sales are distributed geographically as follows: the United States (55.1%), Europe (18.5%) and other (26.4%).

Employees

4,700

Sector

Pharmaceuticals

More about the company